[Increased hematological toxicity of antineoplastic drugs with simultaneous androgenotherapy (author's transl)].
Thirty two patients with malignant lymphoma - mainly Hodgkin's disease - were randomized for simultaneous treatment by high doses of metenolone during MOPP chemotherapy, to reduce its hematological toxicity. The results have shown surprisingly an increased hemato-toxicity in patients receiving androgens, with significantly more marked anemia and thrombocytopenia, reducing the total doses of anti-cancer drugs. This side effect could be explained by a cycling of the hematopoietic stem-cells and call to some caution when androgens are used during cancer chemotherapy.
D000728:Androgens / Q000009:adverse effects* / Q000627:therapeutic use; D000740:Anemia / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008466:Mechlorethamine / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced*; D014750:Vincristine / Q000627:therapeutic use
D000728:Androgens; D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine
Aggravation de la toxicité hématologique d'agents anti-néoplasiques par l'androgénothérapie simultanée.